Mass spectrometry comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-30. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
=== Pharmacology research === Pharmacological studies on synephrine date back to the late 1920s, when it was observed that injected synephrine raised blood pressure, constricted peripheral blood vessels, dilated pupils, stimulated the uterus, and relaxed the intestines in experimental animals. Representative of this early work is the paper by Tainter and Seidenfeld, who were the first researchers to systematically compare the different effects of the two synephrine enantiomers, d- and l- synephrine, as well as of the racemate, d,l-synephrine, in various animal assays. In experiments on anesthetized cats, Tainter and Seidenfeld confirmed earlier reports of the increase in blood pressure produced by intravenous doses of synephrine, showing that the median pressor doses for the isomers were: l-synephrine: 0.5 mg/kg; d,l-synephrine: 1.0 mg/kg; and d-synephrine: 2–20 mg/kg. These effects lasted 2–3 minutes, peaking at ~30 seconds after administration. l-Synephrine was thus the more potent enantiomer, with about 1/60x the potency of the standard pressor l-epinephrine in the same assay. A later study, by Lands and Grant, showed that a dose of ~0.6 mg/kg of racemic synephrine, given intravenously to anesthetized dogs, produced a rise in blood pressure of 34 mmHg lasting 5–10 minutes, and estimated that this pressor activity was about 1/300x that of epinephrine. Using cats and dogs, Tainter and Seidenfeld observed that neither d- nor l-synephrine caused any changes in the tone of normal bronchi, in situ, even at "maximum" doses.
== Intermediates as substrates for biosynthetic processes == In this subheading, as in the previous one, the TCA intermediates are identified by italics. Several of the citric acid cycle intermediates are used for the synthesis of important compounds, which will have significant cataplerotic effects on the cycle. Acetyl-CoA cannot be transported out of the mitochondrion. To obtain cytosolic acetyl-CoA, citrate is removed from the citric acid cycle and carried across the inner mitochondrial membrane into the cytosol. There it is cleaved by ATP citrate lyase into acetyl-CoA and oxaloacetate. The oxaloacetate is returned to mitochondrion as malate (and then converted back into oxaloacetate to transfer more acetyl-CoA out of the mitochondrion). The cytosolic acetyl-CoA is used for fatty acid synthesis and the production of cholesterol. Cholesterol can, in turn, be used to synthesize the steroid hormones, bile salts, and vitamin D. The carbon skeletons of many non-essential amino acids are made from citric acid cycle intermediates. To turn them into amino acids the alpha keto-acids formed from the citric acid cycle intermediates have to acquire their amino groups from glutamate in a transamination reaction, in which pyridoxal phosphate is a cofactor. In this reaction the glutamate is converted into alpha-ketoglutarate, which is a citric acid cycle intermediate. The intermediates that can provide the carbon skeletons for amino acid synthesis are oxaloacetate which forms aspartate and asparagine; and alpha-ketoglutarate which forms glutamine, proline, and arginine.
=== After 1997: return to business === By 1997, when his career as a Cabinet minister ended, Haymarket was making an annual profit of over £10m and employing around 1,000 people. Heseltine resumed management of the company after Masters' retirement in 1999. Haymarket has seen reduced profitability in the UK since 1999, but has expanded further into foreign markets (for example India). It has also laboured under heavy borrowings of over £100 million to buy back Masters' and Tindall's large minority shareholdings, which have been reduced to some extent by the sale of properties. Heseltine has now retired from day-to-day management, handing over to his son Rupert. Heseltine's ownership of Haymarket has made him a large personal fortune. As of 2013 he was ranked 311th in The Sunday Times Rich List with an estimated wealth, including shareholdings held by members of his immediate family, of £264 million.
=== Mic–Mu === Leonor Michaelis (1875–1949). German biochemist at the Rockefeller Institute of Medical Research, known for early work on enzyme kinetics. He developed biochemistry in Japan. He studied quinones, and used this knowledge to develop a method for producing a perm (hairstyle). Friedrich Miescher (1844–1895). Swiss physician and biologist at Leipzig University, the first to isolate DNA. Kenneth R. Miller (born 1948), American evolutionary biologist and author of Finding Darwin's God César Milstein FRS (1927–2002). Argentinian-British biochemist at the University of Cambridge, known for developing the use of monoclonal antibodies. Nobel Prize in Physiology or Medicine (1984). Foreign associate Natl. Acad. Sci. USA. María Teresa Miras Portugal (1948–2021), Spanish biochemist, pharmacist and molecular biologist. Peter D. Mitchell FRS (1920–1992). British biochemist at Glynn Research, known for the theory of chemiosmosis. Nobel Prize in Chemistry (1978). Foreign associate Natl. Acad. Sci. USA. John Keith Moffat (b. 1943), British biophysicist at Argonne National Laboratory known for work on time-resolved crystallography. Catherine Anne Money (b. 1940), Australian biochemist known for revolutionizing leather production Jacques Monod FRS (foreign member) (1910–1976). French biochemist and microbiologist at the Pasteur Institute, known for many discoveries and for the theory of allostery. His philosophical book Chance and Necessity has been influential. Nobel Prize in Physiology or Medicine (1965).
Sources: en.wikipedia.org
Despite DuPont's assertion that "cookware coated with DuPont Teflon non-stick coatings does not contain PFOA", residual PFOA was also detected in finished PTFE products including PTFE cookware (4–75 parts per billion). However, PFOA levels ranged from undetectable (<1.5) to 4.3 parts per billion in a more recent study. Also, non-stick cookware is heated—which should volatilize PFOA; PTFE products that are not heated, such as PTFE sealant tape, had higher (1800 parts per billion) levels detected. Overall, PTFE cookware is considered an insignificant exposure pathway to PFOA.
=== Urea cycle === The urea cycle is a metabolic pathway that results in the formation of urea using one ammonium molecule from degraded amino acids, another ammonium group from aspartate and one bicarbonate molecule. This route commonly occurs in hepatocytes. The reactions related to the urea cycle produce NADH, and NADH can be produced in two different ways. One of these uses oxaloacetate. In the cytosol there are fumarate molecules. Fumarate can be transformed into malate by the actions of the enzyme fumarase. Malate is acted on by malate dehydrogenase to become oxaloacetate, producing a molecule of NADH. After that, oxaloacetate will be recycled to aspartate, as transaminases prefer these keto acids over the others. This recycling maintains the flow of nitrogen into the cell.
Strategic Cyber Security, ISBN 978-9949-9040-7-5, 169 pages Halpern, Sue, "The Drums of Cyberwar" (review of Andy Greenberg, Sandworm: A New Era of Cyberwar and the Hunt for the Kremlin's Most Dangerous Hackers, Doubleday, 2019, 348 pp.), The New York Review of Books, vol. LXVI, no. 20 (19 December 2019), pp. 14, 16, 20. Harris, Shane (2014). @War: The Rise of the Military-Internet Complex. Eamon Dolan/Houghton Mifflin Harcourt. ISBN 978-0-544-25179-3. Hunt, Edward (2012). "US Government Computer Penetration Programs and the Implications for Cyberwar". IEEE Annals of the History of Computing. 34 (3): 4–21. Bibcode:2012IAHC...34c...4H. doi:10.1109/mahc.2011.82. S2CID 16367311. Kestner, Peter (2024). The Art of Cyber Warfare: Strategic and Tactical Approaches for Attack and Defense in the Digital Age (1st ed.). Wiesbaden: Springer. pp. XX, 292. doi:10.1007/978-3-658-43879-1. ISBN 978-3-658-43879-1. Janczewski, Lech; Colarik, Andrew M. (2007). Cyber Warfare and Cyber Terrorism. Idea Group Inc (IGI). ISBN 978-1-59140-992-2. Rid, Thomas (2012). "Cyber War Will Not Take Place". Journal of Strategic Studies. 35 (1): 5–32. doi:10.1080/01402390.2011.608939. S2CID 153828543. Springer, Paul J. (2025). Encyclopedia of Cyber Warfare (2nd ed.). New York: Bloomsbury Academic. p. 464. ISBN 9781440881619. Woltag, Johann-Christoph: 'Cyber Warfare' in Rüdiger Wolfrum (Ed.) Max Planck Encyclopedia of Public International Law (Oxford University Press 2012).
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.